Conclusion
It is a pivotal time in overcoming the current outbreak of the
2019-nCoV. The decoction of the specified drugs listed should be
assessed for their efficacy and safety and stability, and should also be
evaluated for the treatment and recovery of patients suffering from the
2019-nCoV in carefully planned clinical trials, either used alone or
integrated with other drugs. Many of the potential drugs under different
phases of clinical trials (eg: Remdesivir, Lopinavir, Ritonavir,
Darunavir, Cobicistat etc. are in phase III, Oseltamivir is in phase IV
of clinical trials, and many others are in preclinical stage of trials)
can be successful in battling COVID-19 [10][37][43][47].
The vital ethical concern in the COVID-19 setting for the administration
of repurposable drugs are experimental and, thus, require ethical or
off-label approval of trials [55]. We will keep cautiously
optimistic before releasing successful clinical trial results as the
lessons from a recent public panic buying spree, which revealed results
of a preliminary study and induced irrational purchases overnight,
should also be taken into account. In this study, our approach will
reduce the translational gap between preclinical research results and
clinical outcomes, which is a major problem in the rapid production of
successful drugs, discovered for the emerging 2019-nCoV / SARS-CoV-2
outbreak.